Delafloxacin

Synonym(s): BT-492  |  RX-334  |  WQ-3034 (Baxdela)

Class: Fluoroquinolone

Spectrum of activity:	Gram-positive  &  Gram-negative
Details of activity:	Acute bacterial skin and skin structure infections; other potential indications: community-acquired bacterial pneumonia and complicated urinary tract infections
Propensity to select resistant mutants:	Yes
Institute where first reported:	Melinta Therapeutics Inc.
Year first mentioned:	2009 (phase 2 trials)
Highest developmental phase:	Approved by FDA in 2017
Development status:	Approved

Chemical structure(s):
Canonical SMILES:	C1=C(C(=C(C2=C1C(=O)C(=CN2C3=NC(=C(C=C3F)F)N)C(=O)O)Cl)N4CC(C4)O)F
Isomeric SMILES:	C1C(CN1C2=C(C=C3C(=C2Cl)N(C=C(C3=O)C(=O)O)C4=C(C=C(C(=N4)N)F)F)F)O
InChI:	InChI=1S/C18H12ClF3N4O4/c19-12-13-7(1-9(20)14(12)25-3-6(27)4-25)15(28)8(18(29)30)5-26(13)17-11(22)2-10(21)16(23)24-17/h1-2,5-6,27H,3-4H2,(H2,23,24)(H,29,30)
InChI Key:	DYDCPNMLZGFQTM-UHFFFAOYSA-N
Structure link:	https://pubchem.ncbi.nlm.nih.gov/compound/487101

External links:
Guide to Pharmacology:	delafloxacin
Main Source:	http://www.melinta.com/delafloxacin.php
Citations:	https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/208610s000,208611s000lbl.pdf https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6208769/ http://www.sciencedirect.com/science/article/pii/S1201971214016555